Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F14%3A%230000171" target="_blank" >RIV/26475821:_____/14:#0000171 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/14:00076231 RIV/00216208:11140/14:10271887 RIV/00669806:_____/14:10271887

Result on the web

<a href="http://ar.iiarjournals.org/content/34/6/3205.full.pdf+html" target="_blank" >http://ar.iiarjournals.org/content/34/6/3205.full.pdf+html</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib

Original language description

Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. In a total of 144 patients with advanced-stage (IIIBor IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

6

Country of publishing house

GR - GREECE

Number of pages

6

Pages from-to

3205-3210

UT code for WoS article

—

EID of the result in the Scopus database

—